The latest emerging drugs for the treatment of diabetic cardiomyopathy

References

• Dillmann WH. Diabetic cardiomyopathy. Circ Res. 2019 Apr;124(8):1160–1162. doi: 10.1161/CIRCRESAHA.118.314665
   PubMed Web of Science ®Google Scholar
• Pham I, Cosson E, Nguyen MT, et al. Evidence for a specific diabetic cardiomyopathy: an observational retrospective echocardiographic study in 656 asymptomatic type 2 diabetic patients. Int J Endocrinol. 2015 May;2015:743503. doi: 10.1155/2015/743503
   PubMed Web of Science ®Google Scholar
• Park JJ. Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J. 2021 Mar;45(2):146–157. doi: 10.4093/dmj.2020.0282
   PubMed Web of Science ®Google Scholar
• Arnold SV, Khunti K, Bonnet F, et al. Type 2 diabetes and heart failure: insights from the global DISCOVER study. ESC Heart Fail. 2021 Apr;8(2):1711–1716. doi: 10.1002/ehf2.13235
   PubMed Web of Science ®Google Scholar
• Dhar A, Venkadakrishnan J, Roy U, et al. A comprehensive review of the novel therapeutic targets for the treatment of diabetic cardiomyopathy. Ther Adv Cardiovasc Dis. 2023 Jan;17539447231210170. doi: 10.1177/17539447231210170
   Google Scholar
• Tan Y, Zhang Z, Zheng C, et al. Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence. Nat Rev Cardiol. 2020 Sep;17(9):585–607.
   PubMed Web of Science ®Google Scholar
• Jia G, Whaley-Connell A, Sowers JR, et al. Diabetic cardiomyopathy: a hyperglycaemia- and insulin-resistance-induced heart disease Diabetologia. Diabetologia. 2018 Jan;61(1):21–28.
   PubMed Web of Science ®Google Scholar
• Gallo LA, Wright EM, Vallon V. Vallon V Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015 Mar;12(2):78–89. doi: 10.1177/1479164114561992
   PubMed Web of Science ®Google Scholar
• Nasiri-Ansari N, Nikolopoulou C, Papoutsi K, et al. Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-/-) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. 2021 Jan 15;22(2):818. doi: 10.3390/ijms22020818
   PubMed Web of Science ®Google Scholar
• Sun X, Han F, Lu Q, et al. Empagliflozin ameliorates obesity-related cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and Redox Homeostasis in high-fat diet-induced obese mice. Diabetes. 2020 Mar;69(6)1292–1305.
   PubMed Web of Science ®Google Scholar
• Kogot-Levin A, Riahi Y, Abramovich I, et al. Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. JCI Insight. 2023 Apr;8(7):e164296.
   PubMed Web of Science ®Google Scholar
• Arow M, Waldman M, Yadin D, et al. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020 Jan;19(1):7.
   PubMed Web of Science ®Google Scholar
• He L, Li Y, Zhang D, et al. Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1/PGC-1α pathway in obese mice. Biochem Biophys Res Commun. 2022 May;615:123–130. doi: 10.1016/j.bbrc.2022.05.022
   PubMed Web of Science ®Google Scholar
• Durak A, Olgar Y, Degirmenci S, et al. A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats. Cardiovasc Diabetol. 2018 Nov;17(1):144.
   PubMedGoogle Scholar
• Zhou H, Wang S, Zhu P, et al. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol. 2018 May;15:335–346. doi: 10.1016/j.redox.2017.12.019
   PubMed Web of Science ®Google Scholar
• Lyu Y, Huo J, Jiang W, et al. Empagliflozin ameliorates cardiac dysfunction in heart failure mice via regulating mitochondrial dynamics. Eur J Pharmacol. 2023 Mar;942:175531. doi: 10.1016/j.ejphar.2023.175531
   PubMed Web of Science ®Google Scholar
• Zhou Y, Suo W, Zhang X, et al. Targeting mitochondrial quality control for diabetic cardiomyopathy: therapeutic potential of hypoglycemic drugs. Biomed Pharmacother. 2023 Dec;168:115669. doi: 10.1016/j.biopha.2023.115669
   PubMed Web of Science ®Google Scholar
• Byrne NJ, Matsumura N, Maayah ZH, et al. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020 Jan;13(1):e006277.
   PubMed Web of Science ®Google Scholar
• Feng B, Yu P, Yu H, et al. Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes. Diabetol Metab Syndr. 2023 Jun;15(1):141.
   PubMed Web of Science ®Google Scholar
• Yu YW, Zhao XM, Wang YH, et al. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol. 2021 Jan;20(1):25.
   PubMed Web of Science ®Google Scholar
• Huang K, Luo X, Liao B, et al. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms. Cardiovasc Diabetol. 2023 Apr;22(1):86.
   PubMed Web of Science ®Google Scholar
• Girerd N, Zannad F. SGLT2 inhibition in heart failure with reduced or preserved ejection fraction: finding the right patients to treat. J Intern Med. 2023 May;293(5):550–558. doi: 10.1111/joim.13620
   PubMed Web of Science ®Google Scholar
• Packer M, Butler J, Zannad F, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved trial. Circulation. 2021 Oct;144(16):1284–1294.
   PubMed Web of Science ®Google Scholar
• Trang NN, Chung CC, Lee TW, et al. Empagliflozin and liraglutide differentially modulate cardiac metabolism in diabetic cardiomyopathy in rats. Int J Mol Sci. 2021 Jan;22(3):1177.
   PubMed Web of Science ®Google Scholar
• Chevli PA, Freedman BI, Hsu FC, et al. Plasma metabolomic profiling in subclinical atherosclerosis: the diabetes heart study. Cardiovasc Diabetol. 2021 Dec;20(1):231.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang H, Xie X, et al. Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy. Diabetol Metab Syndr. 2023 May;15(1):93.
   PubMed Web of Science ®Google Scholar
• Scisciola L, Chianese U, Caponigro V, et al. Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes. J Transl Med. 2023 Sep;21(1):662.
   PubMed Web of Science ®Google Scholar
• Scisciola L, Taktaz F, Fontanella RA, et al. Targeting high glucose-induced epigenetic modifications at cardiac level: the role of SGLT2 and SGLT2 inhibitors. Cardiovasc Diabetol. 2023 Feb;22(1):24.
   PubMed Web of Science ®Google Scholar
• Donniacuo M, De Angelis A, Telesca M, et al. Atrial fibrillation: epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors. Pharmacol Res. 2023 Feb;188:106591. doi: 10.1016/j.phrs.2022.106591
   PubMed Web of Science ®Google Scholar
• Kadosaka T, Watanabe M, Natsui H, et al. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca2+ handling in ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol. 2023 Mar;324(3):H341–H354.
   PubMed Web of Science ®Google Scholar
• Singh M, Kumar A. Risks associated with SGLT2 inhibitors: an overview. Curr Drug Saf. 2018 Feb;13(2):84–91. doi: 10.2174/1574886313666180226103408
   PubMed Web of Science ®Google Scholar
• Matharu K, Chana K, Ferro CJ, et al. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions. Pharmacol Res Perspect. 2021 Oct;9(5):e00867. doi: 10.1002/prp2.867
   PubMed Web of Science ®Google Scholar
• Yang F, Qin Y, Wang Y, et al. Metformin inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent effects in diabetic cardiomyopathy. Int J Biol Sci. 2019 Mar;15(5):1010–1019.
   PubMed Web of Science ®Google Scholar
• Dawood AF, Alzamil NM, Hewett PW, et al. Metformin protects against Diabetic Cardiomyopathy: an association between desmin-sarcomere injury and the iNOS/mTOR/TIMP-1 fibrosis axis. Biomedicines. 2022 Apr;10(5):984.
   PubMed Web of Science ®Google Scholar
• Abdelsamia EM, Khaleel SA, Balah A, et al. Curcumin augments the cardioprotective effect of metformin in an experimental model of type I diabetes mellitus; impact of Nrf2/HO-1 and JAK/STAT pathways. Biomed Pharmacother. 2019 Jan;109:2136–2144. doi: 10.1016/j.biopha.2018.11.064
   PubMed Web of Science ®Google Scholar
• Zou R, Nie C, Pan S, et al. Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy. Free Radic Biol Med. 2022 Apr;183:35–50. doi: 10.1016/j.freeradbiomed.2022.03.010
   PubMed Web of Science ®Google Scholar
• Eraky SM, Ramadan NM. Effects of omega-3 fatty acids and metformin combination on diabetic cardiomyopathy in rats through autophagic pathway. J Nutr Biochem. 2021 Nov;97:108798. doi: 10.1016/j.jnutbio.2021.108798
   PubMed Web of Science ®Google Scholar
• Jia W, Bai T, Zeng J, et al. Combined administration of metformin and atorvastatin attenuates diabetic cardiomyopathy by inhibiting inflammation, apoptosis, and oxidative stress in type 2 diabetic mice. Front Cell Dev Biol. 2021 Feb;9:634900. doi: 10.3389/fcell.2021.634900
   PubMed Web of Science ®Google Scholar
• Packer M. Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovasc Diabetol. 2020 May;19(1):62. doi: 10.1186/s12933-020-01041-4
   PubMed Web of Science ®Google Scholar
• Kuan IHS, Savage RL, Duffull SB, et al. The association between metformin therapy and lactic acidosis. Drug Saf. 2019 Dec;42(12):1449–1469.
   PubMed Web of Science ®Google Scholar
• Connelly PJ, Lonergan M, Soto-Pedre E, et al. Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: a GoDarts study. Diab Obes Metab. 2017 Nov;19(11):1579–1586.
   PubMed Web of Science ®Google Scholar
• Bell S, Farran B, McGurnaghan S, et al. Risk of acute kidney injury and survival in patients treated with metformin: an observational cohort study. BMC Nephrol. 2017 May;18(1):163.
   PubMedGoogle Scholar
• Almutairi M, Gopal K, Greenwell AA, et al. The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy. Can J Cardiol. 2021 Jan;37(1):140–150.
   PubMed Web of Science ®Google Scholar
• Ding W, Chang WG, Guo XC, et al. Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart. Front Endocrinol. 2019 Apr;10:202. doi: 10.3389/fendo.2019.00202
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials. Diab Obes Metab. 2019 Nov;21(11):2576–2580.
   PubMed Web of Science ®Google Scholar
• Paiman EHM, van Eyk HJ, van Aalst MMA, et al. Effect of Liraglutide on cardiovascular function and myocardial tissue characteristics in type 2 diabetes patients of south Asian descent living in the Netherlands: a double-blind, randomized, placebo-controlled trial. J Magn Reson Imaging. 2020 Jun;51(6):1679–1688.
   PubMed Web of Science ®Google Scholar
• Jorsal A, Kistorp C, Holmager P, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017 Jan;19(1):69–77.
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai F, Li G, et al. Novel dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist attenuates diabetes and myocardial injury through inhibiting hyperglycemia, inflammation and oxidative stress in rodent animals. Bioengineered. 2022 Apr;13(4):9184–9196.
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2015 Feb;11(3–4):202–230. doi: 10.1900/RDS.2014.11.202
   Google Scholar
• Liu L, Chen J, Wang L, et al. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol. 2022 Dec;13:1043789. doi: 10.3389/fendo.2022.1043789
   PubMed Web of Science ®Google Scholar
• Wang L, Cai Y, Jian L, et al. Impact of peroxisome proliferator-activated receptor-α on diabetic cardiomyopathy. Cardiovasc Diabetol. 2021 Jan;20(1):2.
   PubMed Web of Science ®Google Scholar
• Zhang J, Cheng Y, Gu J, et al. Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of type 1 diabetic mice. Clin Sci (Lond). 2016 Apr;130(8):625–641.
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov;366(9500):1849–1861.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018 Dec;206:80–93. doi: 10.1016/j.ahj.2018.09.011
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Ohta Y, Taguchi A, et al. Effects of pemafibrate on left ventricular diastolic function in patients with type 2 diabetes mellitus: a pilot study. Diabetol Int. 2023 Jul;14(4):434–439.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Santos RD. SPPARM alpha: the lazarus effect. Curr Opin Lipidol. 2019 Dec;30(6):419–427. doi: 10.1097/MOL.0000000000000640
   PubMed Web of Science ®Google Scholar
• Yanai H, Katsuyama H, Hakoshima M. A significant increase of estimated glomerular filtration rate after switching from fenofibrate to pemafibrate in type 2 diabetic patients. Cardiol Res. 2021 Dec;12(6):358–362. doi: 10.14740/cr1333
   PubMed Web of Science ®Google Scholar
• Lee HC, Shiou YL, Jhuo SJ, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol. 2019 Apr;18(1):45.
   PubMedGoogle Scholar
• Wei D, Liao L, Wang H, et al. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro. Life Sci. 2020 Sep;247:117414. doi: 10.1016/j.lfs.2020.117414
   PubMed Web of Science ®Google Scholar
• Barreto-Torres G, Parodi-Rullán R, Javadov S. The role of PPARα in metformin-induced attenuation of mitochondrial dysfunction in acute cardiac ischemia/reperfusion in rats. Int J Mol Sc. 2012 Jun;13(6):7694–7709. doi: 10.3390/ijms13067694
   PubMed Web of Science ®Google Scholar
• Bai F, Liu Y, Tu T, et al. Metformin regulates lipid metabolism in a canine model of atrial fibrillation through AMPK/PPAR-α/VLCAD pathway. Lipids Health Dis. 2019 May;18(1):109.
   PubMedGoogle Scholar
• Wu L, Wang K, Wang W, et al. Glucagon-like peptide-1 ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via the PPARα pathway. Aging Cell. 2018 Aug;17(4):e12763. doi: 10.1111/acel.12763.
   PubMed Web of Science ®Google Scholar
• Cai H, Zhou L, Liu J, et al. Independent and combined effects of liraglutide and aerobic interval training on glycemic control and cardiac protection in diabetic cardiomyopathy rats. Biochem Biophys Res Commun. 2022 Nov;629:112–120. doi: 10.1016/j.bbrc.2022.09.018
   PubMed Web of Science ®Google Scholar
• Xie SY, Liu SQ, Zhang T, et al. USP28 serves as a key suppressor of mitochondrial morphofunctional defects and cardiac dysfunction in the diabetic heart. Circulation. 2024 Feb;149(9):684–706.
   PubMed Web of Science ®Google Scholar
• Xiong SP, Sun HJ, Cao X, et al. Polysulfide protects against diabetic cardiomyopathy through sulfhydration of peroxisome proliferator-activated receptor-γ and sirtuin 3. Antioxid Redox Signal. 2023 Jan;38(1–3):1–17.
   PubMed Web of Science ®Google Scholar
• Van Linthout S, Riad A, Dhayat N, et al. Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy. Diabetologia. 2007 Sep;50(9):1977–1986.
   PubMed Web of Science ®Google Scholar
• Abdel-Hamid AA, Ael-D F. Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress. J Mol Histol. 2015 Oct;46(4–5):337–345. doi: 10.1007/s10735-015-9625-4
   PubMed Web of Science ®Google Scholar
• Ren XM, Zuo GF, Wu W, et al. Atorvastatin alleviates experimental diabetic cardiomyopathy by regulating the GSK-3β-PP2Ac-NF-κB signaling axis. PLOS ONE. 2016 Nov;11(11):e0166740.
   PubMed Web of Science ®Google Scholar
• Carillion A, Feldman S, Na N, et al. Atorvastatin reduces β-adrenergic dysfunction in rats with diabetic cardiomyopathy. PLOS ONE. 2017 Jul;12(7):e0180103.
   PubMed Web of Science ®Google Scholar
• Luo B, Li B, Wang W, et al. Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model. Cardiovasc Drugs Ther. 2014 Feb;28(1):33–43.
   PubMed Web of Science ®Google Scholar
• Liberale L, Carbone F, Camici GG, et al. IL-1β and statin treatment in patients with myocardial infarction and diabetic cardiomyopathy. J Clin Med. 2019 Oct;8(11):1764.
   PubMed Web of Science ®Google Scholar
• Attardo S, Musumeci O, Velardo D, et al. Statins neuromuscular adverse effects. Int J Mol Sci. 2022 Jul;23(15):8364.
   PubMed Web of Science ®Google Scholar
• Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021 Jul;374:n1537. doi: 10.1136/bmj.n1537
   PubMed Web of Science ®Google Scholar
• Grewal AS, Thapa K, Kanojia N, et al. Natural compounds as source of Aldose Reductase (AR) inhibitors for the treatment of diabetic complications: a mini review. Curr Drug Metab. 2022;21(14):1091–1116. doi: 10.2174/1389200221666201016124125
   Web of Science ®Google Scholar
• Ramasamy R, Oates PJ, Schaefer S. Aldose reductase inhibition protects diabetic and nondiabetic rat hearts from ischemic injury. Diabetes. 1997 Dec;46(2):292–300. doi: 10.2337/diab.46.2.292
   PubMed Web of Science ®Google Scholar
• Cameron NE, Cotter MA, Robertson S. Contractile properties of cardiac papillary muscle in streptozotocin-diabetic rats and the effects of aldose reductase inhibition. Diabetologia. 1989 Jun;32(6):365–370. doi: 10.1007/BF00277260
   PubMed Web of Science ®Google Scholar
• Gaztanaga J, Ramasamy R, Schmidt AM, et al. A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: results from a registry-based matched-control analysis. Diabetes Metab Syndr. 2021 Nov;15(6):102328.
   PubMed Web of Science ®Google Scholar
• Gopal K, Karwi QG, Tabatabaei Dakhili SA, et al. Aldose reductase inhibition alleviates diabetic cardiomyopathy and is associated with a decrease in myocardial fatty acid oxidation. Cardiovasc Diabetol. 2023 Mar;22(1):73.
   PubMed Web of Science ®Google Scholar
• Haffar T, Bérubé-Simard F, Bousette N. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem Biophys Res Commun. 2015 Dec;468(1–2):73–78. doi: 10.1016/j.bbrc.2015.10.162
   PubMed Web of Science ®Google Scholar
• Li X, Wu F, Günther S, et al. Inhibition of fatty acid oxidation enables heart regeneration in adult mice. Nature. 2023 Oct;622(7983):619–626. doi: 10.1038/s41586-023-06585-5
   PubMed Web of Science ®Google Scholar
• Yong QC, Thomas CM, Seqqat R, et al. Angiotensin type 1a receptor-deficient mice develop diabetes-induced cardiac dysfunction, which is prevented by renin-angiotensin system inhibitors. Cardiovasc Diabetol. 2013 Nov;12(1):169.
   PubMedGoogle Scholar
• Marfella R, D’Onofrio N, Mansueto G, et al. Glycated ACE2 reduces anti-remodeling effects of renin-angiotensin system inhibition in human diabetic hearts. Cardiovasc Diabetol. 2022 Aug;21(1):146. doi: 10.1186/s12933-022-01573-x
   PubMed Web of Science ®Google Scholar
• Batista JPT, Faria AOV, Ribeiro TFS, et al. The role of renin-angiotensin system in diabetic cardiomyopathy: a narrative review. Life (Basel). 2023 Jul;13(7):1598.
   PubMed Web of Science ®Google Scholar
• Rydén L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J. 2000 Dec;21(23):1967–1978.
   PubMed Web of Science ®Google Scholar
• Jin Q, Zhu Q, Wang K, et al. Allisartan isoproxil attenuates oxidative stress and inflammation through the SIRT1/Nrf2/NFκB signalling pathway in diabetic cardiomyopathy rats. Mol Med Rep. 2021 Mar;23(3):215.
   PubMed Web of Science ®Google Scholar
• Malek V, Gaikwad AB. Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy. Cardiovasc Res. 2019 Feb;115(2):373–384. doi: 10.1093/cvr/cvy226
   PubMed Web of Science ®Google Scholar
• Ge Q, Zhao L, Ren XM, et al. LCZ696, an angiotensin receptor-neprilysin inhibitor, ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis. Exp Biol Med (Maywood). 2019 Sep;244(12):1028–1039.
   PubMed Web of Science ®Google Scholar
• Balmforth C, Simpson J, Shen L, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019 Jun;7(6):457–465.
   PubMed Web of Science ®Google Scholar
• Balogh DB, Molnar A, Degi A, et al. Cardioprotective and antifibrotic effects of low-dose renin-angiotensin-aldosterone system inhibitors in type 1 diabetic rat Model. Int J Mol Sci. 2023 Dec;24(23):17043.
   PubMed Web of Science ®Google Scholar
• Blankenburg M, Fett AK, Eisenring S, et al. Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study. BMC Nephrol. 2019 May;20(1):171.
   PubMed Web of Science ®Google Scholar
• Jin T, Fu X, Liu M, et al. Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus. Diabetol Metab Syndr. 2023 Apr;15(1):87.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Filippatos G, Pitt B, et al. FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb;43(6):474–484.
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kolkhof P, Bakris G, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021 Jan;42(2):152–161.
   PubMed Web of Science ®Google Scholar
• Ben Salem C, Badreddine A, Fathallah N, et al. Drug-induced hyperkalemia. Drug Saf. 2014 Sep;37(9):677–692.
   PubMed Web of Science ®Google Scholar
• Dubrall D, Schmid M, Stingl JC, et al. Angioedemas associated with renin-angiotensin system blocking drugs: comparative analysis of spontaneous adverse drug reaction reports. PLOS ONE. 2020 Mar;15(3):e0230632.
   PubMed Web of Science ®Google Scholar
• Jubaidi FF, Zainalabidin S, Taib IS, et al. The potential role of flavonoids in ameliorating diabetic cardiomyopathy via alleviation of cardiac oxidative stress, inflammation and apoptosis. Int J Mol Sci. 2021 May;22(10):5094.
   PubMed Web of Science ®Google Scholar
• Zhang J, Qiu H, Huang J, et al. Naringenin exhibits the protective effect on cardiac hypertrophy via EETs-PPARs activation in streptozocin-induced diabetic mice. Biochem Biophys Res Commun. 2018 May;502(1):55–61.
   PubMed Web of Science ®Google Scholar
• He Y, Wang S, Sun H, et al. Naringenin ameliorates myocardial injury in STZ-induced diabetic mice by reducing oxidative stress, inflammation and apoptosis via regulating the Nrf2 and NF-κB signaling pathways. Front Cardiovasc Med. 2022 Aug;9:946766. doi: 10.3389/fcvm.2022.946766
   PubMed Web of Science ®Google Scholar
• Wu X, Zhou X, Lai S, et al. Curcumin activates Nrf2/HO-1 signaling to relieve diabetic cardiomyopathy injury by reducing ROS in vitro and in vivo. FASEB J. 2022 Sep;36(9):e22505.
   PubMed Web of Science ®Google Scholar
• Ren BC, Zhang YF, Liu SS, et al. Curcumin alleviates oxidative stress and inhibits apoptosis in diabetic cardiomyopathy via Sirt1-Foxo1 and PI3K-Akt signalling pathways. J Cell Mol Med. 2020 Nov;24(21):12355–12367.
   PubMed Web of Science ®Google Scholar
• Wei Z, Pinfang K, Jing Z, et al. Curcumin improves diabetic cardiomyopathy by inhibiting pyroptosis through AKT/Nrf2/ARE pathway. Mediators Inflamm. 2023 Apr;2023:1–20. doi: 10.1155/2023/3906043
   Web of Science ®Google Scholar
• Shafabakhsh R, Mobini M, Raygan F, et al. Curcumin administration and the effects on psychological status and markers of inflammation and oxidative damage in patients with type 2 diabetes and coronary heart disease. Clin Nutr ESPEN. 2020 Dec;40:77–82. doi: 10.1016/j.clnesp.2020.09.029
   PubMed Web of Science ®Google Scholar
• Dastani M, Rahimi HR, Askari VR, et al. Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: evidence of a randomized, double-blinded, placebo-controlled clinical trial. BioFactors. 2023 Jan;49(1):108–118.
   PubMed Web of Science ®Google Scholar
• Lekshmi RK, Divya BT, Mini S. Cissus quadrangularis extract attenuates hyperglycaemia-mediated oxidative stress in streptozotocin-induced diabetic rats. Redox Rep. 2014 Sep;19(5):214–220. doi: 10.1179/1351000214Y.0000000096
   PubMed Web of Science ®Google Scholar
• Syed AA, Reza MI, Shafiq M, et al. Cissus quadrangularis extract mitigates diabetic cardiomyopathy by inhibiting RAAS activation, inflammation and oxidative stress. Biomarkers. 2022 Dec;27(8):743–752.
   PubMed Web of Science ®Google Scholar
• Wei Z, Jing Z, Pinfang K, et al. Quercetin inhibits pyroptosis in diabetic cardiomyopathy through the Nrf2 pathway. J Diabetes Res. 2022 Dec;2022:1–11. doi: 10.1155/2022/9723632
   Web of Science ®Google Scholar
• Jiang C, Li D, Chen L, et al. Quercetin ameliorated cardiac injury via reducing inflammatory actions and the glycerophospholipid metabolism dysregulation in a diabetic cardiomyopathy mouse model. Food Funct. 2022 Jul;13(14):7847–7856.
   PubMed Web of Science ®Google Scholar
• Bartosova L, Horvath C, Galis P, et al. Quercetin alleviates diastolic dysfunction and suppresses adverse pro-hypertrophic signaling in diabetic rats. Front Endocrinol. 2022 Dec;13:1029750. doi: 10.3389/fendo.2022.1029750
   PubMed Web of Science ®Google Scholar
• Fang WJ, Wang CJ, He Y, et al. Resveratrol alleviates diabetic cardiomyopathy in rats by improving mitochondrial function through PGC-1α deacetylation. Acta Pharmacol Sin. 2018 Jan;39(1):59–73.
   PubMed Web of Science ®Google Scholar
• Wang G, Song X, Zhao L, et al. Resveratrol prevents diabetic cardiomyopathy by increasing Nrf2 expression and transcriptional activity. Biomed Res Int. 2018 Mar;2018:2150218. doi: 10.1155/2018/2150218
   PubMed Web of Science ®Google Scholar
• Mohammed Yusof NL, Zainalabidin S, Mohd Fauzi N, et al. Hibiscus sabdariffa (roselle) polyphenol-rich extract averts cardiac functional and structural abnormalities in type 1 diabetic rats. Appl Physiol Nutr Metab. 2018 Dec;43(12):1224–1232.
   PubMed Web of Science ®Google Scholar
• Ding Y, Zhang B, Zhou K, et al. Dietary ellagic acid improves oxidant-induced endothelial dysfunction and atherosclerosis: role of Nrf2 activation. Int J Cardiol. 2014 Aug;175(3):508–514.
   PubMed Web of Science ®Google Scholar
• Zhu N, Huang B, Zhu L, et al. Potential mechanisms of triptolide against diabetic cardiomyopathy based on network pharmacology analysis and molecular docking. J Diabetes Res. 2021 Dec;2021:9944589. doi: 10.1155/2021/9944589
   PubMed Web of Science ®Google Scholar
• Wen HL, Liang ZS, Zhang R, et al. Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy. Cardiovasc Diabetol. 2013 Mar;12:50. doi: 10.1186/1475-2840-12-50
   PubMed Web of Science ®Google Scholar
• Liang Z, Leo S, Wen H, et al. Triptolide improves systolic function and myocardial energy metabolism of diabetic cardiomyopathy in streptozotocin-induced diabetic rats. BMC Cardiovasc Disord. 2015 May;15(1):42.
   PubMedGoogle Scholar
• Huang K, Luo X, Zhong Y, et al. New insights into the role of melatonin in diabetic cardiomyopathy. Pharmacol Res Perspect. 2022 Feb;10(1):e00904.
   PubMed Web of Science ®Google Scholar
• Hung YC, Yang HT, Yin MC. Asiatic acid and maslinic acid protected heart via anti-glycative and anti-coagulatory activities in diabetic mice. Food Funct. 2015 Sep;6(9):2967–2974. doi: 10.1039/C5FO00549C
   PubMed Web of Science ®Google Scholar
• Qin X, Qiu C, Zhao L. Maslinic acid protects vascular smooth muscle cells from oxidative stress through Akt/Nrf2/HO-1 pathway. Mol Cell Biochem. 2014 May;390(1–2):61–67. doi: 10.1007/s11010-013-1956-4
   PubMed Web of Science ®Google Scholar
• Zhang C, Yu H, Ye J, et al. Ginsenoside Rg3 protects against diabetic cardiomyopathy and promotes adiponectin signaling via activation of PPAR-γ. Int J Mol Sci. 2023 Nov;24(23):16736.
   PubMed Web of Science ®Google Scholar
• Yu HT, Zhen J, Pang B, et al. Ginsenoside Rg1 ameliorates oxidative stress and myocardial apoptosis in streptozotocin-induced diabetic rats. J Zhejiang Univ Sci B. 2015 May;16(5):344–354.
   PubMed Web of Science ®Google Scholar
• Farrag EAE, Hammad MO, Safwat SM, et al. Artemisinin attenuates type 2 diabetic cardiomyopathy in rats through modulation of AGE-RAGE/HMGB-1 signaling pathway. Sci Rep. 2023 Jul;13(1):11043.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang S, Ji H, et al. Broccoli sprout extract prevents diabetic cardiomyopathy via Nrf2 activation in db/db T2DM mice. Sci Rep. 2016 Jul;6(1):30252.
   PubMedGoogle Scholar
• Gu J, Cheng Y, Wu H, et al. Metallothionein is downstream of Nrf2 and partially mediates sulforaphane prevention of diabetic cardiomyopathy. Diabetes. 2017 Feb;66(2):529–542.
   PubMed Web of Science ®Google Scholar
• Sanganalmath SK, Dubey S, Veeranki S, et al. The interplay of inflammation, exosomes and Ca dynamics in diabetic cardiomyopathy. Cardiovasc Diabetol. 2023 Feb;22(1):37.
   PubMed Web of Science ®Google Scholar
• Zheng YL, Wang WD, Cai PY, et al. Stem cell-derived exosomes in the treatment of acute myocardial infarction in preclinical animal models: a meta-analysis of randomized controlled trials. Stem Cell Res Ther. 2022 Apr;13(1):151.
   PubMed Web of Science ®Google Scholar
• Bitirim CV, Ozer ZB, Aydos D, et al. Cardioprotective effect of extracellular vesicles derived from ticagrelor-pretreated cardiomyocyte on hyperglycemic cardiomyocytes through alleviation of oxidative and endoplasmic reticulum stress. Sci Rep. 2022 Apr;12(1):5651.
   PubMed Web of Science ®Google Scholar
• Nunez Lopez YO, Casu A, Kovacova Z, et al. Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes. Front Endocrinol. 2022 Aug;13:955593. doi: 10.3389/fendo.2022.955593
   PubMed Web of Science ®Google Scholar
• Huang G, Cheng Z, Hildebrand A, et al. Diabetes impairs cardioprotective function of endothelial progenitor cell-derived extracellular vesicles via H3K9Ac inhibition. Theranostics. 2022 May;12(9):4415–4430.
   PubMed Web of Science ®Google Scholar
• Veitch S, Njock MS, Chandy M, et al. MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol. 2022 Feb;21(1):31.
   PubMed Web of Science ®Google Scholar
• Wang X, Huang W, Liu G, et al. Cardiomyocytes mediate anti-angiogenesis in type 2 diabetic rats through the exosomal transfer of miR-320 into endothelial cells. J Mol Cell Cardiol. 2014 Sep;74:139–150. doi: 10.1016/j.yjmcc.2014.05.001
   PubMed Web of Science ®Google Scholar
• Liu S, Chen J, Shi J, et al. M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment. Basic Res Cardiol. 2020 Feb;115(2):22.
   PubMed Web of Science ®Google Scholar
• Jankauskas SS, Gambardella J, Sardu C, et al. Functional role of miR-155 in the pathogenesis of diabetes mellitus and its complications. Noncoding RNA. 2021 Jul;7(3):39.
   PubMed Web of Science ®Google Scholar
• Groot M, Lee H. Sorting mechanisms for MicroRNAs into extracellular vesicles and their associated diseases. Cells. 2020 Apr;9(4):1044. doi: 10.3390/cells9041044
   PubMed Web of Science ®Google Scholar
• Zhan J, Jin K, Xie R, et al. Ago2 protects against diabetic cardiomyopathy by activating mitochondrial gene translation. Circulation. 2024 Apr;149(14):1102–1120.
   PubMedGoogle Scholar
• Yu LM, Dong X, Xue XD, et al. Melatonin attenuates diabetic cardiomyopathy and reduces myocardial vulnerability to ischemia-reperfusion injury by improving mitochondrial quality control: role of SIRT6. J Pineal Res. 2021 Jan;70(1):e12698.
   PubMed Web of Science ®Google Scholar
• Ding M, Feng N, Tang D, et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway. J Pineal Res. 2018 Sep;65(2):e12491.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhao Z, Feng X, et al. Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition. J Cell Mol Med. 2018 Oct;22(10):5132–5144.
   PubMed Web of Science ®Google Scholar
• Zhang M, Lin J, Wang S, et al. Melatonin protects against diabetic cardiomyopathy through Mst1/Sirt3 signaling. J Pineal Res. 2017 Sep;63(2). doi: 10.1111/jpi.12418
   Web of Science ®Google Scholar
• Che H, Wang Y, Li H, et al. Melatonin alleviates cardiac fibrosis via inhibiting lncRNA MALAT1/miR-141-mediated NLRP3 inflammasome and TGF-β1/Smads signaling in diabetic cardiomyopathy. FASEB J. 2020 Apr;34(4):5282–5298.
   PubMed Web of Science ®Google Scholar
• Raygan F, Ostadmohammadi V, Bahmani F, et al. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019 Feb;38(1):191–196.
   PubMed Web of Science ®Google Scholar
• Hoseini SG, Heshmat-Ghahdarijani K, Khosrawi S, et al. Effect of melatonin supplementation on endothelial function in heart failure with reduced ejection fraction: a randomized, double-blinded clinical trial. Clin Cardiol. 2021 Sep;44(9):1263–1271.
   PubMed Web of Science ®Google Scholar
• Foley HM, Steel AE. Adverse events associated with oral administration of melatonin: a critical systematic review of clinical evidence. Complement Ther Med. 2019 Feb;42:65–81. doi: 10.1016/j.ctim.2018.11.003
   PubMed Web of Science ®Google Scholar
• Zhao M, Wang S, Zuo A, et al. HIF-1α/JMJD1A signaling regulates inflammation and oxidative stress following hyperglycemia and hypoxia-induced vascular cell injury. Cell Mol Biol Lett. 2021 Sep;26(1):40.
   PubMed Web of Science ®Google Scholar
• Vásquez-Trincado C, García-Carvajal I, Pennanen C, et al. Mitochondrial dynamics, mitophagy and cardiovascular disease. J Physiol. 2016 Feb;594(3):509–525.
   PubMed Web of Science ®Google Scholar
• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018 Feb;122(4):624–638. doi: 10.1161/CIRCRESAHA.117.311586
   PubMed Web of Science ®Google Scholar
• Ji Z, Liu GH, Qu J. Mitochondrial sirtuins, metabolism, and aging. J Genet Genomics. 2022 Apr;49(4):287–298. doi: 10.1016/j.jgg.2021.11.005
   PubMed Web of Science ®Google Scholar